Michael Hassett, MD, MPH, discusses the rise of oral therapeutics in breast cancer care, emphasizing patient support, education, and overcoming financial barriers for better outcomes.
Media ReleaseCOPENHAGEN, Denmark; More than 20 abstracts, including seven oral presentations, highlight advancements from the epcoritamab development program supporting the expanded clinical profile ...
Raipur oncologist Dr. Jayesh Sharma stresses that early cancer signs are often subtle and easily overlooked. Persistent, ...
October 2025 proved to be a significant month for the oncology landscape, marked by a wave of key regulatory decisions from the US FDA. This period saw important full and accelerated drug approvals ...
Solomon Islands National Provident Fund (SINPF) is supporting the fight against cancer in the country by donating five ...
Of the 2.3 million women diagnosed annually with breast cancer worldwide, research shows more than half report having ...
First orphan designation ever granted to a condensate-modulating therapeuticBuilds on recent IND opening for DPTX3186, a ...
NetworkNewsWire Editorial Coverage NEW YORK, Oct. 29, 2025 /PRNewswire/ -- The global cancer-therapy landscape is undergoing a rapid evolution toward ...
A new study links gum disease and cavities to an 86 per cent higher risk of ischaemic stroke, highlighting why oral health is ...
Dermatologic side effects from breast cancer treatments include chemotherapy-induced allergic reactions and drug-specific effects like hand-foot syndrome, and immunotherapy-related immune skin ...
Merck on Tuesday said a Phase 3 study evaluating the dual oral regimen of Welireg plus Lenvima met one of its primary endpoints of progression-free survival for the treatment of patients with advanced ...
WHEN a kiss from Sarah Susak’s husband gave her what felt like an electric shock, she didn’t think much of it. But the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback